https://www.globenewswire.com/news-release/2021/09/08/2293324/0/en/XWPharma-Initiates-First-in-Human-Studies-of-XW10508-in-Development-for-Fast-acting-Relief-of-Treatment-Resistant-Depression-and-Chronic-Pain.html
XWPharma Initiates First-in-Human Studies of XW10508, in
XW10508 is an oral, once-daily therapy and novel analog of esketamine, designed for improved tolerability, intended to provide prompt efficacy following...
first in humaninitiatesstudiesxw10508